본문바로가기

INSTRUCTIONS FOR AUTHORS
(Journal of Mycology and Infection)

Journal of Mycology and Infection(JMI) is the official journal of the Korean Society for Medical Mycology. The objective of the journal is to present studies and reports on all aspects of mycology to provide a comprehensive reference or evidence for medical mycologists, microbiologists, and clinicians. All contents of JMI are freely available on the web including downloadable digital files. For policies unstated in this instruction, "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication" (http://www.icmje.org) can be applied. Any physician or researcher can submit a manuscript pertaining with the appropriate scope of the manuscript. Only those manuscripts which are original, have not been published elsewhere, and are not currently being considered for inclusion in another publication will be considered for publication in JMI.



SUBMISSION OF MANUSCRIPTS

All manuscripts should be submitted online via the official website (https://submission-jmi.isway.co.kr/) by the corresponding author. Submission instructions are available at the website. All articles submitted to the journal must comply with these instructions. Failure to do so will result in return of the manuscript and possible delay in publication. Send all correspondence regarding submitted manuscripts to:

Editor in Chief : Jong Soo Choi, MD, PhD (Yeungnam University, South Korea)
Associate Editor in Chief : Hyojin Kim, MD, PhD (Inje University, South Korea)

The Korean Society for Medical Mycology
Division of Infectious Disease, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, #56, Donsu-Ro, Bupyung-Gu, Incheon, 21431, South Korea
Tel: +82-32-280-5882, Fax: +82-32-280-5349, E-mail: muze1004@catholic.ac.kr

The Korean Society for Medical Mycology
JMI publishes a manuscript immediately after acceptance. Publication schedule is usually every three months (quarterly).



RESEARCH AND PUBLICATION ETHICS

The Journal adheres to the ethical guidelines for research and publication described in Good Publication Practice Guidelines for Medical Journals (http://kamje.or.kr/publishing_ethics.html) and Guidelines on Good Publication (http://publicationethics.org/static/1999/1999pdf13.pdf).

Registration of Clinical Trial Research
It is recommended that any research that deals with a clinical trial be registered with a primary national clinical trial registration site, such as http://cris.cdc.go.kr/, or other sites accredited by the WHO as listed at http://www.who.int/ictrp/en/.

Conflict of Interest
Authors are responsible for disclosing all funding sources that support the work as well as all institutional or corporate associations of the authors. This applies not only to stocks but consultant arrangements or other equity ownership, stock options, patent licensing arrangements payments for conducting or publicizing the study, and consulting relationships with investment companies also are included. To prevent ambiguity, authors have to explicitly state whether potential conflicts do or do not exist.

Statement of Informed Consent
Copies of written informed consent and institutional review board (IRB) approval for clinical research must be retained. If necessary, the editor or reviewers may request copies of these documents to resolve issues during the IRB approval process and study conducts. In addition, for studies conducted with human subjects, the method by which informed consent was obtained from the participants (i.e., verbal or written) also needs to be stated in the ‘Methods’ section. If a patient(s) in the manuscripts is discernable, a patient consent form must be obtained and signed by the patient(s). It should be submitted with the manuscript. De-identification of the patients is acceptable.

Patient Consent Form:
The patient consent form for identifying material is accessible here

Statement of Human and Animal Rights
In studies of human subjects, the procedures should be in accordance with the ethical standards of the Institutional Review Board (IRB) of the author's institute and with the Helsinki Declaration in 1975 (revised in 2013). Please refer to the principles embodied in the Declaration of Helsinki (https://www.wma.net/policies-post/wma-declaration­of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/). In the case of animal experiments, authors should follow the institutional or national guidelines according to the 13th Animal Protection Law of Korea with the approval of the Institutional Animal Care and Use Committee. When approved by the Institutional Animal Care and Use Committee, a letter of assent should be submitted when requested. The editor of JMI may demand submission of copies of informed consents from human subjects in clinical studies or IRB approval documents. The JMI will follow the guidelines by the Committee on Publication Ethics (COPE, http://publicationethics.org/) for settlement of any misconduct.

Authorship
Authorship credit should be based on 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual contents; and 3) final approval of the version to be published. Authors should meet these three conditions.

Originality and Duplicate Publication
All submitted manuscripts should be original and should not be considered by other scientific journals for publication at the same time. No part of the accepted manuscript should be duplicated in any other scientific journal without the permission of the Editorial Board. Duplication will be checked through crosscheck (https://app.ithenticate.com/) or eTBLAST (http://etest.vbi.vt.edu/etblast3/) before submission. If duplicate publication related to the papers of the journal is detected, the manuscripts may be rejected, the authors will be announced in the journal, and their institutes will be informed. According penalties may be imposed to the authors. A letter of permission is required for any reproduction or remarks of any material that has been published previously. The author is responsible for obtaining permission from the publisher for any material that is being reproduced. This requirement applies to text, illustrations, and tables.

Secondary Publication
It is possible to republish manuscripts if the manuscripts meet the conditions of secondary publication of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals.



PEER REVIEW PROCESS

All manuscripts will be evaluated double blinded by three peer reviewers who are selected by the editors. The acceptance criteria for all papers are based on the quality and originality of the research and its clinical and scientific significance. Initial decision will normally be made within 3 weeks after the agreement of review by reviewers, and their comments will then be sent to the corresponding authors. Revised manuscripts must be submitted online by the corresponding author. The corresponding author must indicate the alterations that have been made item by item in a response note with the submitted original file traced. Failure to resubmit the revised manuscript within 8 weeks from the editorial decision is regarded as a withdrawal. The editorial office should be notified for additional time delay and retraction of the submission. The editorial committee makes decisions concerning editing, revision, and acceptance or rejection. Editing ranges from shortening articles, reducing the number of illustrations or tables, to changing the paper's format or the order of the manuscript. Authors can track the progress of a manuscript on the journal's website. Articles that are accepted for publication are relocated from the "Manuscripts Accepted" to the "Manuscripts in Publication" section at the official website.



COPYRIGHTS AND CREATIVE COMMONS ATTRIBUTION LICENSE

Once the manuscript is published, property of pertaining materials belongs to the journal. All published papers become the permanent property of the Korean Society for Medical Mycology and must not be published elsewhere without written permission. Copyrights of all published materials are owned by the Korean Society for Medical Mycology. They also follow the Creative Commons Attribution Non-Commercial License available from: http://creativecommons.org/licenses/by-nc/3.0/.



PUBLICATIOIN PROCESSING CHARGES

For unsolicited manuscripts, the corresponding author is asked to a portion of the costs for article processing. The processing charge for a single article is US $50.00 (50,000 Korean won) per page regardless of the type of article. Reprints of 50 copies are US $50.00 (50,000 Korean won) without additional shipping cost.



PREPARATION OF MANUSCRIPTS

General Guidelines

• The manuscript should be typed with Microsoft by leaving 3cm on the top and bottom, separating each line two lines apart, and using 10 points font.

• Agency and the names of authors should not be written in the original file of the paper.

• Research abstracts should be written in English.

• All scientific terms must comply with the latest recent dermatologic glossary published by Korean Dermatology Association. Other terms must be written in compliance with the latest medical glossary published by the Korean Medical Association.

• Words lacking proper translation such as medical terms, proper nouns, units, can be written in their original language. In addition, if translated words do not deliver accurate meanings, the original language can be written in parenthesis following the translated for its first appearance.

• In principle, abbreviations should not be used. However, if the same term is repeated frequently, the word should be used in full initially followed by the abbreviation in parenthesis. Thereafter, the abbreviation only may be used. Abbreviations are not allowed to be used in the abstract.

• Arabian numbers are used for marking numbers, the metric system is used for the measurement, and the measurement examination should be marked based on International System of Units.

• Machines and medicines have to be written in generic name. A trade name should be marked in parentheses such as '®' and 'TM' and the manufacturing company, city and country name should be noted.

• Use the terms sex when reporting biologic factors and genders when reporting gender identity, psychosocial or cultural factors. Report sex, gender, or both of study participants such as humans, animals, tissues, or cells in the methods or results section. If only one sex was enrolled, authors should report the reason why the study was done in an exclusive manner (eg, male pattern baldness or female pattern baldness).

Reporting Guidelines for Specific Study Designs

For specific study designs, such as randomized control studies, studies of diagnostic accuracy, metaanalyses, observational studies, and non-randomized studies, it is recommended that the authors follow the reporting guidelines listed in the following table.



Initiative Type of study URL
CONSORT Randomized controlled trials http://www.consort-statement.org
STARD Studies of diagnostic accuracy http://www.stard-statement.org
PRISMA Preferred reporting items of systematic reviews and meta-analyses http://www.prisma-statement.org
STROBE Observational studies in epidemiology http://www.strobe-statement.org
MOOSE Meta-analyses of observational studies in epidemiology http://www.consort-statement.org/resources/downloads/other-instruments/moose-statement-2000pdf/


OPEN DATA POLICY

For clarification on result accuracy and reproducibility of the results, raw data or analysis data is recommended to be included in the article. Data can be attached as a spate file or included in the manuscript. It can be deposited to a public repository, for example, Harvard Dataverse (https://dataverse.harvard.edu/dataverse/jeehp/) after acceptance of the manuscript. Therefore, submission of the raw data or analysis data is necessary. If the data is already a public one, its URL site or sources should be disclosed. If data cannot be publicized, it can be negotiated with the editor. If data cannot be shared, the authors need to state the reason in. Editors may ask the authors the cause. If there are any inquiries on depositing data, authors should contact the editorial office.



CLINICAL DATA SHARING POLICY

This journal follows the data sharing policy described in "Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors" (https://doi.org/10.3346/jkms.2017.32.7.1051). As of July 1, 2018 manuscripts submitted to ICMJE journals that report the results of interventional clinical trials must contain a data sharing statement as described below. Clinical trials that begin enrolling participants on or after January 1, 2019 must include a data sharing plan in the trial's registration. The ICMJE's policy regarding trial registration is explained at https://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html. If the data sharing plan changes after registration this should be reflected in the statement submitted and published with the manuscript, and updated in the registry record. All of the authors of research articles that deal with interventional clinical trials must submit data sharing plan of example 1 to 4 in Table 1. Based on the degree of sharing plan, authors should deposit their data after deidentification and report the DOI of the data and the registered site.



Table 1. Examples of data sharing statements that fulfill these ICMJE requirements*



Element Example 1 Example 2 Example 3 Example 4
Will individual participant data be available (including data dictionaries)? Yes Yes Yes Yes
What data in particular will be shared? All individual participant data collected during the trial, after deidentification. Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices). Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices). Not available
What other documents will be available? Study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code Study protocol, statistical analysis plan, analytic code Study protocol Not available
When will data be available (start andend dates)? Immediately following publication. No end date. Beginning at 3 months and ending at 5 years following the article publication. Beginning at 9 months and ending at 36 months following the article publication. Not applicable
With whom? Anyone who wishes to access the data. Researchers who provide a methodologically sound proposal. Investigators whose proposed use of the data has been approved by an independent review committee ("learned intermediary") identified for this purpose. Not applicable
For what types of analyses? Any purpose To achieve aims in the approved proposal. For individual participant data meta-analysis. Not applicable
By what mechanism will data be made available? Data are available indefinitely at (link to be included). Proposals should be directed to xxx@yyy. To gain access, data requestors will need to sign a data access agreement. Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata. Not applicable
Data are available for 5 years at a third-party website (link to be included). Information regarding submitting proposals and accessing data may be found at (link to be provided).

ICMJE = International Committee of Medical Journal Editors.

*These examples are meant to illustrate a range of, but not all, data sharing options.



FORMS OF PUBLICATION

A. Original Articles

Title Page: A by-line below the title should include each author's name with institutional affiliation, city and zip code and country. A running title of not more than 50 characters including spaces must be furnished. Any information concerning sources of financial support should also be placed in the foot note. The entire word count should not exceed 3,500 words excluding the abstract, references, figures, and tables. It is required to include the manuscript word count on the title page.

• Abstracts and Key Words: The abstract should explain major findings, significance and the principal conclusion of the study in less than 250 words. Abstracts of the original articles should be organized as below:

- Background : What is the major problem that prompted the study?
- Objective : What is the purpose of the study?
- Methods : How was the study done?
- Results : What are the most important findings?
- Conclusion : What is the single most important conclusion?

These headings must be assigned before each description. Abbreviations, if needed, should be kept to absolute minimum with proper identifications. Abstracts for case report may deviate from this format, but carry the same estrictions of word count. The key words (6 items or less) should be appended to the abstract in alphabetical order. For the selection of keywords, refer Medical Subject Heading (MeSH) in Index Medicus, or in internet site, http://www.nlm.nih.gov/mesh/MBrowser.html.

• Introduction: Brief background, references to the most pertinent papers generally enough to inform readers, and relevant findings of others are described. The objective of the study should also be described.

• Materials and Methods: Explanation of the experimental methods should be concise but sufficient enough to be replicated by qualified investigators. Where previously published procedures are concerned, only new and significant modifications need complete explanation. The sources of special chemicals or preparations used should be given along with their locations (name of company, city and state, and country). Method of statistical analyses and criteria of significance level should be described. In Case Reports, case history or case description replace the Materials and Methods section as well as the Results section.

• Results: This section should include a concise textual description of the data presented in tables and/or figures. The Results and Discussion may be combined if by doing so, space is saved or the logical sequence of the manuscript is improved. Excessive repetition of table or figure contents should be avoided.

• Discussion: The data should be interpreted concisely without repeating materials already presented in the Results section. Speculation is permitted, but it must be supported by the data presented by the authors and be the well founded.

• Acknowledgment: All persons who have made substantial contribution, but who are not eligible as authors are named in acknowledgment. Statement of all funding sources for this work may be described in this section.

•Tables: Tables should be typed double-spaced, each on a separate page. The tables should be numbered and contain a brief specific title. The data presented in the table must be logically and clearly organized; it should be self-explanatory and should supplement, not duplicate the text. The Table's legend may include any pertinent notes and must include definitions of all abbreviations and acronyms that have been used in the Table. For footnotes, the following symbols should be used in this sequence: *, †, ‡, §, ∥, ¶, **, ††, ‡‡, etc. Authors are obligated to indicate the significance of their observations by appropriate statistical analysis.

• Illustrations (Figures): Figures may be submitted in electronic format. Images should be provided as JPG or GIF file less than 2M. The images need to be at least 300 DPI. Figures must be cited in the text and numbered in the order of appearance. The legends of illustration should be placed at the end of the manuscript and referred to as 'Fig.' followed by Arabic numbers. Where a figure has more than one panel, each panel should be labeled as follows: Fig. 1A, Fig. 1B. Legends must be double-spaced. Symbols, arrows, or letters used in photographs should contrast with background. A legend for each light microscopic photograph should include name of stain and magnification. Electron microscopic photograph should have an internal scale marker. All kinds of figures may be reduced, enlarged or trimmed for publication by the Editor. If an illustration has been published previously, full credit to the original source must be given in the legend.

• References: The reference should be numbered in text by order of citation and the bibliography should be prepared in the same order. References from journals should include authors, title, and name of the Journal, year, volume, and inclusive page numbers. When there are seven or more authors, list only the first six and add 'et al.' References cited in the text should indicate the last name(s) of the author(s). When there are more than three authors for each, only the last name of the first author followed by 'et al.' should be indicated. References from chapter in books should include author(s), chapter title, editors, book title, edition, city of publication and publisher, year, and inclusive page numbers. References from books should include the above information with the omission of chapter title and editors.

Example of Reference:

<Journal Articles>

1. Kim DH, Lee JD, Cho SH, Oh SJ. Clinical study of dermatologic disorders in patients with breast cancer. Korean J Dermatol 2004;42:1285-1293 2. Cho SH, Strickland I, Tomkinson A, Fehringer AP, Gelfand EW, Leung DYM. Preferential binding of Staphylococcus aureus to skin sites of Th2-mediated inflammation in a murine model. J Invest Dermatol 2001;116:658-663

<Books>

3. Odom RB, James WD, Berger TG. Andrew's diseases of the skin. 9th ed. Philadelphia: WB Sauders, 2000:69-76

<Chapters in edited Books>

4. Leung DYM, Eichenfield LF, Boguniewicz M. Atopic dermatitis. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, editors. Fitzpatrick's dermatology in general medicine. 6th ed. New York: McGraw-Hill, 2003:1180-1194

<Conference Proceedings>

5. Yoon CH, Ro YS. A case of vesiculobullous Darier's disease. Korean J Dermatol 2004;42(Suppl. 1): 149

6. Sohnle PG, Hahn BL, Fassel TA, Kushnaryov VM. Analysis of fluconazole's effects on Candida albicans viability during extended incubations. Proceedings of the 13th Congress of the International Society for Human and Animal Mycology, 1997 Jun 8-13; Parma, Italy

B. Review Articles

Review articles aim to publish comprehensive analyses of recent advances in laboratory or clinical research. The word count should be around 3,500 words excluding the abstract, references, figures, and tables. Manuscripts include a Title page (with a running head), Abstract and Key words, Text, References, Tables, and Figures. Review articles require abstract in less than 250 words written in free style.

C. Case Reports

JMI includes only case reports of novel and extraordinary significance. Case reports must include an unstructured abstract. Case reports should not exceed 1,500 words, 20 references. Up to 4 figures or tables are allowed for every case report.

D. Letter to the Editor: Research Letters, Comments and Case Letters

The Letter to the Editor section of JMI is divided into 3 sections: Research Letters, Comments, and Case Letters. The sequence for Letter to the editor is Title page, Text, References, Tables and Figures of authors. This section does not require abstracts. The text is written without subdivision and without extra-spacing between paragraphs. Research and case letters are subject to expert review. Research letters should not exceed 1,000 words and 10 references. For comments and Case letters, they should not exceed 500 words and 5 references. It is required to include the word count on the title page. Two figures or tables are allowed for the Letter to the Editor. Up to two figures may be included in a multi-part figure such as figures 1A and 1B. This is considered as one figure.

1) The Research letter section is intended as a form of rapid publication for new or preliminary original research findings and early reports of therapeutic trials. Pilot studies require Institutional Review Board approval. Conclusions based on uncontrolled trials and/or limited experience should be stated in appropriately tentative terms.
2) The Comments section may be in response to issues from previously published articles, or short, free-standing opinion. A comment is usually signed by no more than three authors; this is because Comments section is for readers' opinion, not for statements by organizations or groups of individuals.
3) The Case Letters contain concise descriptions detailing one or two patients and early reports of new drug reactions. A Case Letter should not simply describe an interesting patient but should have a certain level of scholastic value.

E. Images in mycology

JMI accepts a category of submission, specified as images in mycology. Submitted images should provide high-quality photographs of common to extraordinary cases relevant to mycology bearing educational values. The image scope includes from clinical, pathological, radiologic, to laboratory examinations. An abstract is not required. The draft, in principle, should be written in English, should not exceed 250 words of body text, and is limited to 3 references. The maximum numbers of authors are 4. The number of figure should be one, however multi-panel figures are permitted. The text should be submitted in a concise and scholarly style.

ABSTRACTING AND INDEXING

A part of articles in JMI, metadata or full text of JMI is available from KoreaMed and JMI homepage (http:// www.e-jmi.org). It can be seen in search results in SCOPUS as a Medline-sourced title.



ARCHIVING POLICY

According to the deposit policy (self-archiving policy) of Sherpa/Romeo (http://www.sherpa.ac.uk/), authors cannot archive pre-print (i.e. pre-refereeing), but they can archive post-print (i.e. final draft post-refereeing). Authors can archive publisher's version/PDF. JMI provides the electronic backup and preservation of access to the journal content in the event the journal is no longer published.



COPYRIGHTS, OPEN ACCESS POLICY, OPEN DATA POLICY, AND CLINICAL DATA SHARING POLICY

Copyright

Copyright to all published materials is owned by the Korea Health Personnel Licensing Examination Institute (formerly National Health Personnel Licensing Examination Board of Korea). The corresponding author should agree to the copyright transfer during the submission process. The Editorial Board takes it granted that the co-authors also accept the copyright transfer per the acceptance by the corresponding author, who has a responsibility of submitting the copyright transfer agreement to the publisher.



Open access policy

• JMI is an open access journal. Articles are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To use the tables or figures of JMI in other periodicals, books or media for scholarly, educational or even commercial purposes, the process of permission request to the publisher of JMI is not necessary. This is in accordance with the Budapest Open Access Initiative definition of open access.

• It also follows the open access policy of PubMed Central at United States National Library of Medicine (http:// www.ncbi.nlm.nih.gov/pmc/).

• All contents of the journal are available immediately upon publication without embargo period.



DETAILED DESCRIPTION ON THE USE OF THE ARTICLES OF JMI

• Reader Benefit: Publisher applies the Creative Commons Attribution License to works it publishes & allows free immediate access to original works of all types.

• Reuse Benefit: Publisher applies the Creative Commons Attribution License to works it publishes & allows unrestricted reuse of original works of all types.

• Copyrights: Publisher applies the Creative Commons Attribution License to works it publishes. Under this license, even though the publisher owns the copyright, anyone can download, reuse, reprint, modify, distribute and/or copy the contents.

• Author Posting Benefit: Publisher applies the Creative Commons Attribution License to works it publishes. Under this license, even though the publisher owns the copyright, authors are allowed to post the post-print version or final PDF version.

• Automatic Posting: Publisher immediately deposits the accepted articles in JMI homepage (http://www.e-jmi.org) upon publication.

• Machine Readability: JMI articles can be accessed programmatically through KoreaMed. For inquiries, please contact at 20050078@kuh.ac.kr

HOW THE JOURNAL HANDLE COMPLAINTS AND APPEALS

The policy of JMI s primarily aimed at protecting the authors, reviewers, editors, and the publisher of the journal. If not described below, the process of handling complaints and appeals follows the guidelines of the Committee of Publication Ethics available from: https://publicationethics.org/appeals



Who complains or makes an appeal?

Submitters, authors, reviewers, and readers may register complaints and appeals in a variety of cases as follows: falsification, fabrication, plagiarism, duplicate publication, authorship dispute, conflict of interest, ethical treatment of animals, informed consent, bias or unfair/inappropriate competitive acts, copyright, stolen data, defamation, and legal problem. If any individuals or institutions want to inform the cases, they can send a letter via the contact page us (20050078@kuh.ac.kr). For the complaints or appeals, concrete data with answers to all factual questions (who, when, where, what, how, why) should be provided.



Who is responsible to resolve and handle complaints and appeals?

The Editor, Editorial Board, or Editorial Office is responsible for them. A legal consultant or ethics editor may be able to help with the decision making.



What may be the consequence of remedy?

It depends on the type or degree of misconduct. The consequence of resolution will follow the guidelines of the Committee of Publication Ethics (COPE).



ADVERTISING POLICIES

JMI accepts commercial pharmaceutical product advertisements. The journal does not accept medical products which have been not approved by KFDA (Korea Food and Drug Administration) or FDA (US Food and Drug Administration). All advertisements must obviously identify the advertiser by trademark or signature.



DIRECT MARKETING

Journal propagation has been done through the journal website and distribution of an introduction pamphlet. Invitations to submit a manuscript are usually focused on the presenters at conferences, seminars, or workshops if the topic is related to the journal's aims and scope.



Congratulatory MessageClick here!